Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Blood-brain barrier transport of docosahexaenoic acid and expression of fatty acid binding protein 5 are decreased in Alzheimer’s disease
- In: Short Communications A3 on Tuesday, 23 May 2017, 11:15-12:30
- At: Stockholm (Sweden) (2017)
- Type: Presentation
- By: NICOLAZZO, Joseph (Monash University, Drug Delivery, Disposition and Dynamics, Parkville, Australia)
- Co-author(s): Joseph Nicolazzo: Drug Delivery, Disposition and Dynamics, Monash University, Parkville, Australia
Yijun Pan: Drug Delivery, Disposition and Dynamics, Monash University, Parkville, Australia
Jennifer Short: Drug Discovery Biology, Monash University, Parkville, Australia
Martin Scanlon: Medicinal Chemistry, Monash University, Parkville, Australia
Christopher Porter: Drug Delivery, Disposition and Dynamics, Monash University, Parkville, Australia - Abstract:
Backgrounds
Fatty acid binding protein 5 (FABP5) is a cytoplasmic protein which regulates the blood-brain barrier (BBB) transport of docosahexaenoic acid (DHA). DHA is an essential polyunsaturated fatty acid required for cognitive function and its brain levels are decreased in Alzheimer’s disease (AD).
Aims
To identify whether FABP5 deficiency leads
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023